By: IPP Bureau
Last updated : April 17, 2026 4:08 pm
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Morepen Laboratories Limited successfully cleared a United States Food and Drug Administration (USFDA) inspection at its Masulakhanna facility in Himachal Pradesh with zero observations (NIL Form 483), marking its fourth consecutive clean inspection over the past eight years.
The milestone reinforces the company’s standing in regulated markets and highlights the robustness of its quality management systems, data integrity frameworks, and compliance culture. According to the company, the consistent NIL 483 track record enhances its credibility with global regulators and positions it for long-term supply agreements.
Morepen has aligned its manufacturing and quality processes with evolving global standards, including ICH and CFR guidelines, while investing significantly in digitalization and automation to improve traceability and operational efficiency.
With exports spanning over 80 countries, the company remains a key supplier of active pharmaceutical ingredients (APIs) to regulated markets such as the US and Europe. Building on its regulatory success, Morepen is now accelerating its expansion into the contract development and manufacturing organization (CDMO) space, leveraging its infrastructure and compliance track record.
The latest inspection outcome further strengthens customer confidence and underscores Morepen’s strategic push to deepen its presence in global pharmaceutical supply chains.